Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 1;22(5):1333-1349.
doi: 10.31557/APJCP.2021.22.5.1333.

Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis

Harmanjeet Kaur  1 , J S Thakur  1 , Ronika Paika  1 , Shailesh M Advani  2
Affiliations
Meta-Analysis

Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis

Harmanjeet Kaur et al. Asian Pac J Cancer Prev. .

Abstract

Background: The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality.

Methods: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients.

Results: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)].

Conclusion: Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services.<br />.

Keywords: COVID-19; Carcinoma; Case fatality; Prevalence; review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of Our Selection Process (PRISMA flow Chart)
Figure 2
Figure 2
Forest Plots for Meta-Analyses of Prevalence of Co-Morbidities
Figure 3
Figure 3
Meta-Analyses of Mortality in SARS CoV-2 Infected Cancer Patients by Co-Morbidity
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aries JA, Davies JK, Auer RL, et al. Clinical outcome of Coronavirus disease 2019 in haemato-oncology patients. B J Haem. 2020;190:e57–e94. - PMC - PubMed
    1. Awadhesh KS, Clare LG, Ritu S, et al. Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis. Diabetes Obes Metab. 2020;22:1915–24. - PMC - PubMed
    1. Basse C, Diakite S, Servois V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr. 2020;5 - PMC - PubMed
    1. Basu P. Healthcare systems need to be organized to fight two pandemics simultaneously. Asian Pac J Cancer Care. 2020;5:1–3.
    1. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2 - PMC - PubMed